Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Marketing heating up in this space! Revance can’t let guard down, should be an interesting 2nd half, 2024
https://www.fiercepharma.com/marketing/abbvie-starts-open-casting-call-next-faces-botox-ads-doubling-down-pitch-everyday-users
I believe this is for Ken Griffins own account
https://ir.protaratx.com/static-files/2cffa79d-9e22-4a12-a866-5308e96d8bad
--Oppenheimer Adjusts Protara
Therapeutics Price Target to $30
From $26
MT Newswires 08:44AM ET, 04/22/2024
‘Proud’ naked seller that if exercised will have a 2 handle, and almost a 1 after taking in $.40( SMH)
Sell to Open 50 Contracts
RVNC Oct 18 2024 2.5 Puts Limit at $0.40 (Good 'til
Canceled)
-RVNC241018P2.5 PUT (RVNC) REVANCE
THERAPEUTICSOCT 18 24
$2.5 (100 SHS)
Filled at $0.40 Apr-16-2024
Bluebird management should read and learn this!! wtf !! K & Q’s too !! Delayed again!!
Ok, lol bye .08, looking like double digits ???
Road block @ .08 again
Level 2 shows 500k
Will also be buying $3ish print today as well as currently offering out 50 puts @ $2.5 strike(Oct 18th expire) …
Yes sir, agreed..mainly it’s regarding 3rd Tranche, and if he can share any color( which is doubtful, but never know til you ask) or do we have to wait for Q1 CC…Will update if anything meaningful
Pretty sure this is the same Laurence( his says New Street) that is the contact person, but just him VM and start repore
Investors
Laurence Watts, 619-916-7620
laurence@newstreetir.com
Wow, I was thinking same question if she can share without recourse by HR…after losing Jessica, I lost a good contact that could answer some simple , legal questions ..
Ms.D,
Thank You for all the Insightful Information and although you put your employment on the line( ie-if “HR”alerted—not suggesting anything nefarious nor insider trading, whistleblow) I / we appreciate what you’re going thru!!!!
… and as an investor who is also down ~$350k+ (main account), I hope you continue and thrive at Revance..sadly the majority of my ‘circle’ of friends
(Palm Beaches, perhaps the most plastic place on earth other than Bev Hills, etc.) never have heard of Daxxy!! And although my 2 buds own the most successful practice’s here, they offer but seemingly not major supporters of the product ( at first it was the pricing, then duration claims) and now most disturbingly Foley/Management!!! I’m trying to touch base with them again to see if Foley is personally reaching out( especially to the larger of the 2 who boasted about his ‘friendship and respect/admiration) for him but had since waned :(
Curious, in your humble and noticeably informed opinion, is there another internal candidate, or perhaps more probable a person outside who could replace Foley?? Any internal ‘cooler’ discussions that you can share without recourse?
Thanks again and keep the faith, one way or another, many of US believe the company will prosper with or w/out Mark!!!!
GLTA
Almost 100% increase in share count( major dilution) …Market Cap pre offering ~$46mm and Post equals ~$75mm( todays price)…yes, better balance sheet, positive interim data..all in all good news, but Arbs will mess around for a bit until Funds buy again…
Jesse is pretty good steward of capital, so when q1 is reported we will see what intrinsic value is ..GLTA
Anybody following Protara( TARA) and its advancement in NMIBC ( ..announced positive data from three-month evaluable carcinoma in situ (CIS) patients treated across its ongoing clinical program of TARA-002, the Company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations.
and IV Choline Chloride (IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.
Approximately 80% of PN patients are choline deficient, which can lead to liver damage and hepatic failure; ASPEN recommends choline replacement for PN patients)
https://ir.protaratx.com/news-releases/news-release-details/protara-therapeutics-announces-alignment-fda-registrational-path
https://ir.protaratx.com/news-releases/news-release-details/protara-therapeutics-announces-positive-three-month-data-tara
https://ir.protaratx.com/news-releases/news-release-details/protara-therapeutics-announces-oversubscribed-45-million-private
Small float, cash runway I believe to Q1, 2026(completed PP ~$45mm)
( have sizable position, not trying to talk book but just curious the potential in both Indications)????
Thanks in advance !
After learning of Jessica’s departure, now I understand why no reply to my email( in the past she was quick to answer the best she could) :
Hi again Jessica, hope you had a wonderful Easter 🐣 😊
Have we drawn on the final tranche
With Athyrium Capital ( I believe upto $100-150mm was the number) ?? If so, can we anticipate an 8-K filing expeditiously? Or do We have to wait until Q1 to be alerted?
Thanks in advance,
M*#%+ B
Private Investor
More consolidation:
ARCA biopharma And Oruka Therapeutics Announce Merger Agreement, The Deal Is Expected To Close in Q3 Of 2024
Benzinga 2024-04-03T07:32:00-04:00
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases
Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025
Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027
Any (especially Foley) Insider Open Mkt purchase lifts this Oinker up 💯, sadly that’s still a single digit number, SMH :(
ON the bright side, I have a $4handle print, can we get a 3 ???
Market watch ( as of 3/15/24) = % OF FLOAT SHORTED
17.93%
On the CC , it was like the 3rd rail seeing not 1 of the analysts ( respectable peeps,-GS, MS, RJ, etc.) asked( if my recall is correct) …mgmt didn’t even guide (LYFGENIA- sickle cell) with clarity other than to say 50% of the 85-100 patient starts across 62 qualified treatment centers (QTCs) …a Q&A regarding TAM ( worldwide-all 3 fda approved indications ) was mid single digits ( ~3B+I believe)… so it’s wait and see what Q1, 24’ conf call suggests..
My take away is that they are going at this alone
( US) and will consider collaborating in other countries once they understand Payers & Regulations and who to dance with ….
Market digesting late 10k /amend and maybe short covering perhaps( thought I saw 15-18%)
Hear ya!!!
Well, NOT that IT matters ( vote,lmao), it does feel good to show them how I/we feel:) lol :) …certainly being down 6 figure$ is painful, I do believe in the science and the market will correct the price( higher in 2nd half, 24’— with or without Foley, et al….
2024 Annual Meeting To be held Wednesday, May 1, 2024
Your voting directions for this meeting (Control Number:
669386751637****) were received on March 27, 2024
at 6:37 a.m. ET.
Here's how you voted:
1. Vote Board of Directors:
1 Election of Director: Angus C. Russell
2 Election of Director: Julian S. Gangolli
3 Election of Director: Olivia C. Ware
You Voted: Withhold
2. Ratification of the selection of
PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
You Voted: For
3. Approval of, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.
You Voted: Against
GLTA
Yes(accounting screw-ups), AND this management burns exorbitant amounts of cash consistently, but the Hercules Credit Facility should provide runway until Q1, 2026 per CC 🙏
Q1/2, 24’ should be decent considering several patients (ZYNTEGLO, SKYSONA) starts (cell collections) and Sickle cell( LYFGENIA) in Q3/4…
Hopefully Kevin Tang continues to build position(~1.7mm sh), as well as other Funds…
This kind of reminds me of RV*C, not sure what Rollout has been worse! ( and perhaps Mgmt) :(
However, Long both and accumulating 🙏
Pretty sure Eman will get a rise out of the last paragraph:)
Mark J. Foley Mr. Foley has more than thirty years of leadership, commercial, operational, business development and investment experience in healthcare, 14 years of which have been in aesthetics. His prior experience includes ZELTIQ Aesthetics, Inc. (acquired by Allergan Inc.), RWI Ventures, U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly & Co.), Perclose (acquired by Abbott Laboratories) and Ventrica (acquired by Medtronic PLC). Mr. Foley’s tenure as CEO of ZELTIQ Aesthetics, Inc., a medical device company that developed non- invasive procedures for the reduction of unwanted fat, culminated in the acquisition of the company by Allergan for $2.5 billion in 2017, which created significant value for shareholders. Mr. Foley also has served on a number of other public and private company boards, providing him with relevant and valuable experience as our Board discharges its duties.
( We believe Mr. Foley is the right leader to steer the Company into its next phase of growth as the Company seeks to expand its market opportunity due to the breadth of his experience in the aesthetics industry, his prior executive leadership experiences in the healthcare space and “due to his track record of delivering stockholder value”).
Non- Independent Director since 2019 Independent Director 2017 - 2019 Positions Revance Therapeutics, Inc. • Chief Executive Officer (October 2019 – present) ZELTIQ Aesthetics • Chairman, President and CEO (2012 – 2017) RWI Ventures • Managing Member (2004 – 2018) Ventrica, Inc. • Founder, CEO (1998 – 2004)
FWIW- proxy vote upon Us:
LETTER FROM CHAIRMAN OF THE BOARD
Dear Fellow Stockholders: On behalf of the Board of Directors (the “Board”), I thank you for your continued support of Revance Therapeutics, Inc. (the “Company” or “Revance”). The Board remains strongly engaged with the strategic oversight of the business, working closely with management to ensure the Company’s strategy serves the needs of its customers while aiming to drive long-term value for its stakeholders. In-line with these objectives, 2023 was a year marked by both achievement and change for Revance. We accomplished foundational milestones including the commercial launch of DAXXIFY ® in aesthetics, the diversification and expansion of our supply chain, and the FDA approval of DAXXIFY for cervical dystonia, our first therapeutics indication. We also navigated the challenges and opportunities associated with the launch of DAXXIFY and took action to drive greater capital and operational efficiencies - all with the goal of positioning the business for long-term success. In 2023, we delivered record total product revenue of $213 million, representing an increase of 80% year-over-year, driven by the commercial launch of DAXXIFY for glabellar lines and the continued success of the RHA ® Collection of dermal fillers. Listening and responding to market feedback continues to be core to our aesthetics strategy and in particular, the launch of DAXXIFY. To that end, we took early learnings from our measured DAXXIFY launch to make the necessary adjustments to our pricing and customer engagement strategies in order to position the product for meaningful share gain and to strengthen our partnerships with our customers. While these changes have had an impact on our stock price, the early results we are seeing with respect to sales volume growth and positive feedback from customers continue to give us confidence in our strategy and long-term blockbuster potential in the U.S. facial injectables market. In 2024, we set our first product revenue guidance of at least $280 million, and the organization is very focused on achieving that objective. Sustainable growth remains a key area of focus for the Board and management. To that end, we have seen tremendous support across the organization to drive greater operating efficiencies, reduce costs where possible and focus our dollars on actions that have the potential to drive the highest returns to stockholders. In 2023, Revance divested its Fintech Platform payments business to prioritize capital for the growth of its aesthetics and therapeutics businesses, streamlined the organizational structure and realized meaningful efficiencies across its manufacturing and supply chain, among other departments. More recently, we completed an equity offering, raising gross proceeds of $100 million, which further enhanced our financial flexibility to invest in our growth while managing our capital structure. We believe these efforts have positioned us to lower our anticipated operating expenses by 6%, while increasing our product sales by at least 32% in 2024. The Board will continue to provide strategic oversight over Revance’s operating plan and capital management to support its objective to reach positive Adjusted EBITDA 1 in 2025. With the significant milestone of receiving the FDA’s approval of DAXXIFY for the treatment of cervical dystonia (“CD”), we are poised to expand our growth trajectory by bringing to market the first compelling treatment alternative for CD patients in 30 years. Our launch readiness with payers, along with the positive feedback from physicians and patients from our DAXXIFY CD PrevU program, underscore the product’s innovation and our unique opportunity to disrupt the therapeutic botulinum toxin market, beginning with CD. We look forward to unlocking additional value from our therapeutics pipeline as we learn more from our CD launch this year and our strategic partnerships with Fosun Pharma and Viatris, which are all progressing steadily. 2024 will be an important year for Revance as we advance our commercial growth through our innovative aesthetics portfolio and enter the large and growing therapeutics market with DAXXIFY. To best capitalize on these opportunities, we have identified the following strategic priorities for the year. 2024 Strategic Priorities Aesthetics: • Grow DAXXIFY and the RHA ® Collection of dermal fillers revenue and market share through deeper and broader account penetration. • Build strong provider partnerships through robust engagement initiatives and thought leadership efforts. • Engage with customers through competitive pricing and enhanced messaging that highlights DAXXIFY’s unique peptide formulation, long duration, fast onset and improved skin quality appearance. Therapeutics: • Successfully complete DAXXIFY CD PrevU program, leveraging learnings and real-world clinical insights to support commercial success. • Launch DAXXIFY for cervical dystonia mid-year under targeted commercial strategy. 1 Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization, stock-based compensation and extraordinary items such as restructuring and impairment charges.
• Secure ~50% commercial coverage by commercial launch for CD, which has already been completed as of the date of this letter. Focused and disciplined capital allocation: • Remain focused on disciplined capital allocation with ongoing operational efficiencies to support path to break- even and Adjusted EBITDA 1 in 2025. In closing, it is an honor to serve as your Chairman, and on behalf of the Board, I thank you for your continued support and investment in Revance. We look forward to your participation at our virtual annual meeting on May 1, 2024.
Very truly yours,
Angus C. Russell
Chairman of the Board of Directors
March 21, 2024
Our latest publication on glabellar lines optimization (GLO 3 + 2) injection technique is now available online in Plastic and Reconstructive Surgery-Global Open! Check out the study here:
https://lnkd.in/gUZUe6GZ
Oh, I’ve been buying equity and also going naked Puts( most likely 6000 shrs will be ‘put’ to me in July) …when my 2 buddies stop offering Daxxy, then I will be concerned ( Aesthetica Institute & Pinsky P.S) ..also have shares in smaller retirement accts..bought more recently, but in smaller lots, and most likely will wait to see Q1 results before adding ( or not)
FWIW:
Hello M*#+%,
Thank you for your email. Revance will issue a press release announcing the date of its Q1 2024 earnings call. Historically, the call has been held in early May.
Best regards,
Revance Investor Relations( lmao, pretty generic but didn’t expect much from ask)
Revance Therapeutics
$4.87 -50.32 (-6.17%)
Overview
Research
Positions
Acquired
Quantity
Average cost
Nov-18-2022
3,000
$22.77
Jul-27-2023
500
$22.99
Jul-27-2023
500
$21.85
Sep-19-2023
800
$20.50
Sep-20-2023
2,000
$20.50
Sep-25-2023
200
$20.50
Jan-03-2024
2,000
$8.60
Mar-08-2024
5,000
$5.99
RVNC
10,000 shares
RVNC 5 Put D
Jul 19 2024
-40 contract (M)
RVNC 7.5 Put ?
Jul 19 2024
-20 contract (M)
‘Small company filer’ has 90 days to file 10k/q (fiscal year end)
Agree 💯..said same awhile back DTC marketing the key for additional adoption!! This below from Social media
(Alle*)
botoxcosmetic • Sponsored
DOUBLE POINTS
DOUBLE UP AND SAVE!
EARN DOUBLE Alle POINTS
WHEN TREATED WITH
BOTOX® COSMETIC AND JUVÉDERM® FILLER
AT THE SAME VISIT FROM 02/02-04/12
AND SAVE ON FUTURE TREATMENTS
THE SAFE AND EFFECTIVE USE OF THESE PRODUCTS HAS NOT BEEN STUDIED TOGETHER.
DOUBLE POINTS ON JUVÉDERM® FILLERS ONLY. TERMS AND CONDITIONS APPLY.
BOTOX
COSMETIC onabotulinumtoxinA
injection
JUVÉDERM®
💯 concur, and wonder what their budget $$$ is for Aesthetics ( specifically Dysport) which I doubt is in prospectus for competitive purposes)…haven’t had chance to review, but will peruse later…
$2.6B to grow the company…and Dysport muscled up to compete in Bonts & fillers?? How does this affect Revance and the others?
https://www.google.com/url?q=https://endpts.com/galderma-targets-2-6b-ipo-with-top-of-the-range-share-pricing/&sa=U&sqi=2&ved=2ahUKEwiI6rehqYWFAxWiibAFHTo4BgYQFnoECCcQAQ&usg=AOvVaw1QjCrgQ7Q-LJ68cDcS4ljx
Maybe we need our own Demi?? Is Taylor ready for a BONT??
https://www.fiercepharma.com/marketing/merz-adds-another-star-its-galaxy-xeomin-partners-tapping-demi-lovato-push-botox-rival
Thanks Dew, will look deeper into the data related to Car-T and CarNk trials…so far ( to date) it seems both candidates are tracking well, maybe it’s the 3rd ( CB-012 / AML Leukemia) ( always a difficult indication to advance ) …I know PFE took equity position previously, and they did Cap raise a few mos.ago, so don’t think it near term dilution..Thx again
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
Anybody follow CRBU??
Caribou Biosciences Inc 5.78 -1.44 (-19.94%)
Corp update seemed positive, so buy rumor, sell news?? Everything seems positive??
https://ih.advfn.com/stock-market/NASDAQ/caribou-biosciences-CRBU/stock-news/93466752/caribou-biosciences-reports-fourth-quarter-and-ful
Fireside chat at 11:20am (est.)…stay tuned
Foley pretty much confirmed the need for raise was
Related to ‘noise’ in the market regarding the credit facility…overhang is over, lol :) buy buy buy !!
Ditto! Picked up 5k @ $5.99 today…also sold naked puts( 5 strike/jul)…likely will sell naked Oct. 5strike
( ~ $1.25 per..only 5 O/I )
RVNC JUL 19 2024 $5 PUT
SO.9300 +S0.1300 (16.2500%)
Positions
Total value
-$4,000.00
Contracts owned
-40
Average cost
$1.06
Total gain/loss
+$252.88 (+5.94%)
Today's gain/loss
-$800.00 (-25.00%)
As of Mar-04-2024 4:43:14 p.m. ET
Purchase history
Acquired
- quantity
Average cost
Jan-11-2024
20
$1.03
Jan-24-2024
20
$1.09
Cool, gonna try and pick some off @ $6
True, and probably even if we had NOBO List, that wouldn’t be totally accurate as well( but closer)…I know it’s irrelevant, but that number stuck out , lol ..